Literature DB >> 22846199

Early assessment of radiation response using a novel functional imaging modality -- [18F]fluorocholine PET (FCH-PET): a pilot study.

Bhupesh Parashar1, A Gabriella Wernicke, Samuel Rice, Joseph Osborne, Prabhsimranjot Singh, Dattatreyudu Nori, Shankar Vallabhajosula, Stanley Goldsmith, K S Clifford Chao.   

Abstract

AIM: [¹⁸F]Fluorodeoxyglucose-positron emission tomography/computerized tomography (FDG-PET) is commonly used to assess response to patients treated with radiation (RT) or combination of chemotherapy and RT (CRT). The intent of this pilot study is to explore whether [¹⁸F]fluorocholine PET (FCH-PET) can serve as an early predictive biomarker for early detection of RT/CRT response.
MATERIALS AND METHODS: Fourteen patients have been accrued and analyzed. The lesions were base of tongue, tonsil, nodes, hypopharynx, maxilla, palate, lung, pancreas, brain, uterine, and rectal. There were 16 lesions that were considered target lesion and were followed for correlation between change in FCH-PET SUVmax readings and clinical outcome. Median tumor size was 4.4 cm. Median RT dose was 66 Gy. The change in SUVmax (Δ SUVmax) of FCH-PET scans performed before and during RT was correlated with clinical outcome at the last follow-up.
RESULTS: The median FCH-PET SUVmax for the 1st and 2nd scans was 6.15 and 4.65, respectively. Fourteen (87.5%) lesions showed a reduction in SUVmax in either a complete response (CR) or a partial response (PR), and 2 lesions showed an increase in SUVmax both of which were determined to be non-response (NR). The median percentage change between the 1st and 2nd scan was -19.5%. Forty-four percent of lesions (7/16) had CR, 44% (7/16) had PR, and 12% (2/16) had NR (no response). Median follow-up was 12 months. The results showed a difference between NR and PR, between NR and CR, and a trend towards significance (p=0.06).
CONCLUSION: FCH-PET scan demonstrated changes in SUVmax during RT that were predictive of final outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22846199      PMCID: PMC3807867     

Source DB:  PubMed          Journal:  Discov Med        ISSN: 1539-6509            Impact factor:   2.970


  22 in total

1.  Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer.

Authors:  K M Greven; D W Williams; W F McGuirt; B A Harkness; R B D'Agostino; J W Keyes; N E Watson
Journal:  Head Neck       Date:  2001-11       Impact factor: 3.147

2.  Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography.

Authors:  L A Farber; F Benard; M Machtay; R J Smith; R S Weber; G S Weinstein; A A Chalian; A Alavi; D I Rosenthal
Journal:  Laryngoscope       Date:  1999-06       Impact factor: 3.325

3.  Uses and limitations of FDG positron emission tomography in patients with head and neck cancer.

Authors:  M M Hanasono; L D Kunda; G M Segall; G H Ku; D J Terris
Journal:  Laryngoscope       Date:  1999-06       Impact factor: 3.325

4.  Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.

Authors:  M Lonneux; G Lawson; C Ide; R Bausart; M Remacle; S Pauwels
Journal:  Laryngoscope       Date:  2000-09       Impact factor: 3.325

5.  Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.

Authors:  N J Fischbein; O S AAssar; G R Caputo; M J Kaplan; M I Singer; D C Price; W P Dillon; R A Hawkins
Journal:  AJNR Am J Neuroradiol       Date:  1998-08       Impact factor: 3.825

6.  FDG-PET scan in local follow-up of irradiated head and neck squamous cell carcinomas.

Authors:  Claude Conessa; Stephane Hervé; Herve Foehrenbach; Jean-Luc Poncet
Journal:  Ann Otol Rhinol Laryngol       Date:  2004-08       Impact factor: 1.547

7.  Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.

Authors:  Tatsuo Torizuka; Toshihiko Kanno; Masami Futatsubashi; Hiroyuki Okada; Etsuji Yoshikawa; Fumitoshi Nakamura; Munetaka Takekuma; Makoto Maeda; Yasuomi Ouchi
Journal:  J Nucl Med       Date:  2003-07       Impact factor: 10.057

8.  Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.

Authors:  A David McCollum; Steven C Burrell; Robert I Haddad; Charles M Norris; Roy B Tishler; Mary Ann Case; Marshall R Posner; Annick D Van den Abbeele
Journal:  Head Neck       Date:  2004-10       Impact factor: 3.147

9.  Positron emission tomography in the early follow-up of advanced head and neck cancer.

Authors:  Gerhard W Goerres; Daniel T Schmid; Florian Bandhauer; Pia U Huguenin; Gustav K von Schulthess; Stephan Schmid; Sandro J Stoeckli
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-01

10.  Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate.

Authors:  Mitsuyoshi Yoshimoto; Atsuo Waki; Atsushi Obata; Takako Furukawa; Yoshiharu Yonekura; Yasuhisa Fujibayashi
Journal:  Nucl Med Biol       Date:  2004-10       Impact factor: 2.408

View more
  4 in total

1.  Diffusion-weighted MRI and 18F-FDG PET correlation with immunity in early radiotherapy response in BNL hepatocellular carcinoma mouse model: timeline validation.

Authors:  Yi-Hsiu Chung; Ching-Fang Yu; Shao-Chieh Chiu; Han Chiu; Shin-Ting Hsu; Ching-Rong Wu; Chung-Lin Yang; Ji-Hong Hong; Tzu-Chen Yen; Fang-Hsin Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-24       Impact factor: 9.236

Review 2.  Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer.

Authors:  Shahil Amin; Oliver F Bathe
Journal:  BMC Cancer       Date:  2016-11-05       Impact factor: 4.430

Review 3.  Monitoring for Response to Antineoplastic Drugs: The Potential of a Metabolomic Approach.

Authors:  Jodi Rattner; Oliver F Bathe
Journal:  Metabolites       Date:  2017-11-16

Review 4.  Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response Monitoring.

Authors:  Amarnath Challapalli; Eric O Aboagye
Journal:  Front Oncol       Date:  2016-02-29       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.